<DOC>
	<DOC>NCT02537249</DOC>
	<brief_summary>Dexmedetomidine is a selective Î±2 adrenergic agonist that can be considered analgesics, anxiolytic,and anti-stress effect . This randomized, double-blind placebo-controlled trial of intraoperative dexmedetomidine for improvement of quality of recovery and analgesia from surgery. Patients scheduled to undergo video-assisted thoracoscopic surgery (VATS) will be enrolled. Patients will be recruited before the date of their surgery and will complete the Quality of Recovery-40 (QoR-40) questionnaire before their surgery and at 24 and 48 hours post op. They will also complete clinically significant pains score and oxygenation from the postanesthetic recovery unit (PACU).</brief_summary>
	<brief_title>Effects of Dexmedetomidine on Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1. The inclusion criteria included patients scheduled videoassisted thoracoscopic surgery for lung cancer 2. Adults above 20 years of age and providing informed consent. 3. American Society of Anesthesiologists (ASA) Physical class II, &amp; III patients 1. severe functional liver or kidney disease 2. history of chronic pain requiring opioid treatment 3. arrhythmia or received treatment with antiarrythmic drug . 4. severe bradycardia (HR &lt; 45 bpm) and AV block 5. pathologic esophageal lesion (esophageal stricture or varix ) 6. pregnancy 7. psychiatric/central nervous system disturbance that would preclude completion of the QoR40 questionnaire 8. History of alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>dexmedetomidine</keyword>
	<keyword>quality of recovery</keyword>
</DOC>